Tyra Biosciences IncNASDAQ:TYRA
- LAST PRICE18.5000
- TODAY'S CHANGE (%)1.1500 (6.6282%)
- Bid / Lots18.1300/ 1
- Ask / Lots19.2000/ 35
- Open / Previous Close17.6100 / 17.3500
- Day Range
- 52 Week Range
- Volume86,080
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TYRA |
|---|---|---|
| 09:32 ET | 1372 | 17.61 |
| 09:48 ET | 200 | 17.76 |
| 09:54 ET | 300 | 17.66 |
| 10:48 ET | 734 | 17.87 |
| 10:51 ET | 100 | 17.92 |
| 11:13 ET | 100 | 17.845 |
| 11:22 ET | 100 | 17.845 |
| 11:27 ET | 205 | 17.84 |
| 11:31 ET | 2599 | 17.99 |
| 11:33 ET | 300 | 18.11 |
| 11:40 ET | 2680 | 18.22 |
| 11:44 ET | 1826 | 18.35 |
| 11:47 ET | 293 | 18.2063 |
| 12:07 ET | 749 | 18.27 |
| 12:14 ET | 200 | 18.21 |
| 12:16 ET | 300 | 18.2 |
| 12:45 ET | 100 | 18.09 |
| 12:52 ET | 200 | 18.1 |
| 12:54 ET | 489 | 18.13 |
| 01:03 ET | 100 | 18.145 |
| 01:06 ET | 403 | 18.14 |
| 01:10 ET | 100 | 18.21 |
| 01:32 ET | 100 | 18.21 |
| 01:35 ET | 200 | 18.19 |
| 01:37 ET | 100 | 18.225 |
| 01:39 ET | 132 | 18.225 |
| 01:50 ET | 300 | 18.225 |
| 01:55 ET | 100 | 18.26 |
| 02:04 ET | 100 | 18.26 |
| 02:06 ET | 100 | 18.26 |
| 02:13 ET | 106 | 18.16 |
| 02:15 ET | 1299 | 18.31 |
| 02:20 ET | 206 | 18.39 |
| 02:27 ET | 200 | 18.38 |
| 02:31 ET | 1124 | 18.27 |
| 02:33 ET | 100 | 18.34 |
| 02:40 ET | 6811 | 18.48 |
| 02:42 ET | 900 | 18.53 |
| 02:44 ET | 200 | 18.54 |
| 02:45 ET | 100 | 18.54 |
| 02:47 ET | 400 | 18.55 |
| 02:49 ET | 100 | 18.55 |
| 02:54 ET | 100 | 18.53 |
| 03:00 ET | 2007 | 18.52 |
| 03:02 ET | 378 | 18.48 |
| 03:07 ET | 644 | 18.42 |
| 03:18 ET | 200 | 18.37 |
| 03:23 ET | 100 | 18.375 |
| 03:27 ET | 200 | 18.31 |
| 03:30 ET | 100 | 18.3 |
| 03:34 ET | 200 | 18.295 |
| 03:36 ET | 100 | 18.32 |
| 03:41 ET | 300 | 18.34 |
| 03:43 ET | 100 | 18.395 |
| 03:48 ET | 100 | 18.36 |
| 03:50 ET | 200 | 18.415 |
| 03:52 ET | 1200 | 18.45 |
| 03:54 ET | 600 | 18.495 |
| 03:56 ET | 2414 | 18.59 |
| 03:57 ET | 3348 | 18.585 |
| 03:59 ET | 2680 | 18.5 |
Today
May 10, 2024
DJ Tyra Biosciences Price Target Maintained With a $28.00/Share by Wedbush, from 9:54AM ET on Friday May 10, 2024 by Dow Jones
9:54AM ET on Friday May 10, 2024 by Dow JonesDJ Tyra Biosciences Price Target Maintained With a $23.00/Share by HC Wainwright & Co., from 7:51AM ET on Friday May 10, 2024 by Dow Jones
7:51AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights, from 4:05PM ET on Thursday May 09, 2024 by Dow Jones
4:05PM ET on Thursday May 09, 2024 by Dow JonesPress Release: Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights, from 4:05PM ET on Thursday May 09, 2024 by Dow Jones
4:05PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tyra Biosciences Inc | 911.3M | -11.0x | --- |
Zentalis Pharmaceuticals Inc | 890.5M | -3.5x | --- |
Viridian Therapeutics Inc | 887.1M | -3.2x | --- |
Cassava Sciences Inc | 874.9M | -8.9x | --- |
89Bio Inc | 856.9M | -4.3x | --- |
ARS Pharmaceuticals Inc | 846.9M | -15.5x | --- |
Company Information
Tyra Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. Its initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. Its lead product candidate, TYRA-300, is an investigational, oral, FGFR3-selective inhibitor being evaluated in an international, multi-center, open label Phase 1 clinical study, SURF301. Its second oncology product candidate, TYRA-200, is an investigational, oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations, and clinically important molecular brake and gatekeeper resistance mutations.
Contact Information
- Headquarters
- 2656 State StreetCARLSBAD, CA, United States 92008
- Phone
- 619-728-4760
- Fax
- 302-655-5049
Executives
- Non-Executive Chairman of the Board
- Robert More
- President, Chief Executive Officer, Treasurer, Director
- Todd Harris
- Chief Financial Officer
- Alan Fuhrman
- Chief Operating Officer
- Daniel Bensen
- General Counsel, Company Secretary
- Ali Fawaz
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $911.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.68 |
Book Value | $4.75 |
P/E Ratio | -11.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
